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Background: Mutations in the genes encoding B, C, and D subunits of the succinate
dehydrogenase (SDH) are involved in the pathogenesis of familial paraganglioma (PGL) syn-
drome. Many subjects with apparently sporadic extra-adrenal paragangliomas are found to
be carrier for SDH mutation. Objective: Here we describe four subjects with apparently
sporadic extra-adrenal paragangliomas with newly identified mutations in the SDH subunit
B and the related clinical phenotype.Methods:Gene sequencing was performed to search
for mutations in the SDHB (all exons), SDHC (all exons), and SDHD (all exons) genes as
well asVHL (all exons) and RET (10, 11, 13, 14, 15, 16 exons) genes in all four index cases.
A complete clinical, biochemical, and instrumental work-up was performed. Results:Three
subjects were found to be affected with a nonsense SDHB germline mutation (Q30X,
Y61X, andW201X, respectively). These mutations are predicted to encode for a truncated
SDHB protein. The fourth subject presented a S195del frameshift mutation, causing a
deletion of the codon AGC, encoding for a serine. Clinical presentation and course of each
patient is described. Conclusions: Extra-adrenal paragangliomas, localized in the sympa-
thetic ganglia (in the posterior thorax or in the abdomen), are very often SDHB-inherited
form rather than sporadic tumor. Our data confirm the importance of genetic screening in
patients affected with paragangliomas and enlarge the list of mutations responsible for the
presence of these tumors.
Keywords: extra-adrenal paragangliomas, germ-line mutations, succinate dehydrogenase subunit B, genetic
screening
INTRODUCTION
Extra-adrenal paragangliomas (PGLs) arising in the thorax and
in the abdomen are sympathetic in origin and generally cate-
cholamine secreting (Baysal, 2002).
Alterations of the mitochondrial complex II or succinate dehy-
drogenase (SDH), which catalyzes the oxidation of succinate to
fumarate in the Krebs cycle and is involved in the aerobic electron
transport chain, have been shown to predispose to PGL formation
(King et al., 2006).
Germline mutations in genes encoding the structural
(SDHD, SDHC) and catalytic (SDHB) succinate dehydroge-
nase subunits predispose to hereditary paraganglioma syn-
dromes named PGL-1 (OMIM #168000), PGL-3 (OMIM
#605373), and PGL-4 (OMIM #115310), respectively (Baysal
et al., 2000; Astuti et al., 2001, 2003; Neumann et al.,
2002).
Germline mutations in SDHD (PGL-1) are associated with
non-secreting, multiple head and neck paragangliomas (HN
PGLs) and less frequently with pheochromocytomas (PHEOs)
and abdominal PGLs, whereas SDHC mutations (PGL-3)
have been associated with benign, solitary HN PGLs (Neu-
mann et al., 2004; Schiavi et al., 2005; Benn et al., 2006),
and more recently also with abdominal PGLs (Mannelli
et al., 2007). SDHB mutations (PGL-4) are mainly associ-
ated with extra-adrenal abdominal or thoracic secreting PGLs
(sPGLs; Gimenez-Roqueplo et al., 2002; Neumann et al.,
2004; Amar et al., 2005; Benn et al., 2006). Moreover, at
variance with PGL-1 and PGL-3, which generally display a
benign phenotype, PGL-4 develops into metastatic disease with
higher frequency (30–70% of cases) (Gimenez-Roqueplo et al.,
2003).
The SDHB gene is located at chromosome 1p35–36.1. Muta-
tions in SDHB gene are inherited as autosomal dominant traits,
and this gene behaves like an oncosuppressor.
Therefore SDHB mutation carriers have a greater risk to
develop extra-adrenal and malignant tumors (Young et al., 2002;
Gimenez-Roqueplo et al., 2003).
To date 177 SDHB gene sequence variants have been
described, distributed as following: 78 missenses, 20 nonsenses,
47 frameshifts, 20 splicesites, 12 large deletions. These variations
have been associated with different type of tumors, ranging from
HN PGLs, PHEOs, abdominal, or thoracic PGLs, either benign or
malignant.
In this paperwe describe four subjects with apparently sporadic
extra-adrenal paragangliomas with newly identified mutations in
the SDH subunit B and the related clinical phenotype.
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PATIENTS AND METHODS
PATIENT 1
A 18-year-old man was evaluated for arterial hypertension. A clin-
ical and morpho-functional assessment was performed: urinary
catecholamines were elevated and magnetic resonance imaging
(MRI) showed a 5.5 cm abdominal lesion in left paravertebral
region. A scintigraphy with 123I-metaiodobenzyl-guanidine 123I-
(MIBG) showed a high uptake in the corresponding site. For
the control of hypertension, the patient started anti-hypertensive
therapy.
The patient underwent surgical resection of the lesion, which
was confirmed to be a PGL at the pathological examination. A
post-surgical assessment was performed three months later: blood
pressure was normal as well as urinary catecholamine levels. Anti-
hypertensive drugswere discontinued and 123I-MIBGscintigraphy
resulted negative.
Three years after surgery, the patient was again affected with
arterial hypertension. For this reason anti-hypertensive ther-
apy was resumed. Catecholamine levels were normal. 123I-MIBG
scintigraphy and MRI were negative. At present, no other lesions,
potentially associated to PGL have been detected. Genetic analy-
sis revealed the presence of a mutation of the SDHB gene
(Figure 1A). The genetic analysis was then extended to first-
degree relatives and the father of the patient resulted to be carrier
of the mutation without any apparent ongoing disease. Any-
way, he refused to undergo biochemical and morpho-functional
evaluations.
Interestingly, the patient’s brother developed hypertension, but
the genetic analysis resulted negative (Figure 2A).
PATIENT 2
A43-year-oldwomanpresented at the SurgicalUnit for a suspicion
of abdominal PGLwith functional syndrome. Sixteen years before,
a mass between inferior cava vein and aorta had been highlighted
by a computed tomography (CT) scan. However, the patient nei-
ther decided to undergo surgery nor to refer to an endocrinologist.
As soon as hypertension, tachycardia, and moderate weight loss
developed, the patient was then referred to our Endocrinology
Department. At the biochemical work-up, increased concentra-
tions of urinary catecholamines andplasma chromogranin-Awere
found, while a 123I-MIBG scintigraphy showed a high uptake in
the site of the abdominal mass. The patient underwent surgical
resection of the tumor that was confirmed to be a PGL (5.5 cm of
maximal diameter) at the pathological examination. The genetic
analysis revealed the presence of a mutation in the SDHB gene
(Figure 1B).
Six months after surgery, there was relapse of mild arterial
hypertension, associated to high levels of urinary catecholamines
and plasma chromogranin-A. An abdomen MRI showed loco-
regional persistence of tumor mass with an extensive infiltra-
tion of the inferior cava vein. This area showed a high uptake
at the somatostatin receptor scintigraphy, as well as an area of
high uptake in the spinal cord, described as a bone metastasis
at the MRI. For this reason, therapy with somatostatin analogs
was started. Furthermore, the patient underwent trans-arterial
embolization of the tumor. At the CT scan re-evaluation, the
mass was unchanged. Due to the persistence of hypertension
FIGURE 1 | (A) Electropherogram showing the germline mutation denoted
with arrow: wild type (left) and mutated patient 1 (right).
(B) Electropherogram of wild type (left) and mutated patient 2 (right).
(C) Electropherogram of wild type (left) and mutated patient 3 (right).
(D) Electropherogram of wild type (left) and mutated patient 4 (right).
and high levels of catecholamines, therapy with sunitinib was
started in combination with somatostatin analogs. A CT scan
performed after three cycles of therapy with sunitinib revealed a
partial response of the abdominal tumor mass and stable vertebral
metastasis.
The genetic analysis was extended to two sisters: one of them
was positive and her clinical history revealed she had been affected
by a renal cell carcinoma, but apparently she had no signs and
symptoms related to PGL (Figure 2B).
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FIGURE 2 | Pedigree of the four families under investigation: family (A) corresponds to Patient 1; family (B) corresponds to Patient 2; family (C)
corresponds to Patient 3; family (D) corresponds to Patient 4.
PATIENT 3
A23-year-oldmanwas referred to our EndocrinologyDepartment
for the follow-up of an abdominal PGL already operated during
childhood and subsequently relapsed. At the age of 12 years, he
had been operated for appendicitis. During the surgical interven-
tion, an abdominal mass was incidentally found and an excisional
biopsy was performed. The pathological examination confirmed
the diagnosis of PGL. Afterward, the patient underwent two sur-
gical interventions which were not able to completely remove the
tumor mass.
At the 123I-MIBG scintigraphy, the persistent abdominal PGL
was negative, while a 68GaDOTATATE-PET revealed the tumor
to express somatostatin receptors. For this reason, the patient
started therapy with somatostatin analogs and underwent a
radiometabolic treatment with 90Y-DOTATATE.
When the patient was first referred to our Endocrinol-
ogy Department, he had local relapse of the disease, associ-
ated with multiple bone metastases. At the biochemical eval-
uation, chromogranin-A levels were high, as well as uri-
nary catecholamines and urinary vanilmandelic acid. At the
radiological assessment there was evidence of progressive
abdominal disease. Therapy with somatostatin analogs was con-
tinued and therapy with sunitinib was started. The genetic
analysis revealed the presence of a mutation in the SDHB
gene (Figure 1C). Patient’s mother and sister underwent the
genetic analysis and they both resulted negative. Patient’s
father has been never investigated because he was unavailable
(Figure 2C).
PATIENT 4
A 25-year-old pregnant woman was evaluated for hypertension.
Due to the unsatisfactory blood pressure control she underwent
cesarean surgery during the seventh month of pregnancy. After
delivery, a CT scan of the abdomen revealed the presence of two
abdominal lesions: the first, on the right side, 5.5 cm of maximal
diameter, apparently was not clearly separable from the underly-
ing tissues, the inferior cava vein and the aorta; the second, on the
left side, 2 cm of maximal diameter, was localized at para-aortic
level. A strong uptake at the 123I-MIBG scintigraphy and elevated
urinary catecholamine concentrations were consistent with the
diagnosis of PGLs. On this basis, the patient underwent surgical
resection of the abdominal lesions. The pathological examination
confirmed the diagnosis of PGL. The genetic analysis revealed the
presence of a mutation in the SDHB gene (Figure 1D). Interest-
ingly, an accurate clinical history revealed that the patient’smother
had been already operated for a PGL. Therefore, mother, brother
and daughter of the patient underwent genetic analysis. The first
two were positive, while the third one was negative. Anyway, the
brother had no apparent disease (Figure 2D).
After surgery, blood pressure levels progressively improved
until a complete normalization. At the last control, 18months
after surgery, urinary metanephrines, and catecholamines as well
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Table 1 | Germline mutations affecting SDHB and related phenotype.
Patient ID cDNA nucleotide Amino acid change Exon Type of tumor
Patient 1 c.88C>T p.Glu30X 2 Paravertebral PGL
Patient 2 c.183T>A p.Tyr61X 3 Abdominal PGL with bone metastasis
Patient 3 c.603G>A p.Trp201X 6 Abdominal PGL with multiple skeletal metastases
Patient 4 c.586_589delAGC p.S195fs 5 Multiple abdominal PGLs
as blood pressure levels were normal. Later on she moved into
another city and was unavailable for follow-up.
METHODS
Written informed consent was obtained from all the four patients
undergoing genetic test in agreement with the guidelines of our
Ethical Committees.
DNA was extracted from peripheral blood leukocytes using
the commercial kit NucleoSpin Blood L (Macherey-Nagel, Düren,
Germany) following the manufacturer’s instructions.
Searching for germline mutations we analyzed SDHB (all
exons), SDHC (all exons), and SDHD (all exons) genes as well as
VHL (all exons) and RET (10, 11, 13, 14, 15, 16 exons) genes. All
the gene coding regions and exon-intron boundaries were ampli-
fied by PCR using the appropriate primers as previously described
(Simi et al., 2005).
PCR products, purified using a PCR purification kit (Qia-
gen, Milan, Italy) following the protocol instructions and semi-
quantified in a 2% agarose ethidium bromide gel using DNA mol-
ecular weight (Roche, IN, USA), were sequenced by ABI PRISM
310 Genetic Analyzer (Applied Biosystems Milan, Italy).
Genetic analysis was extended to the family members who
consented to be studied. After informed consent, genomic DNA
was screened for directed research of described SDHB muta-
tions using PCR and sequencing. Family members who were
found to be carriers of the mutation underwent extensive clini-
cal and laboratory investigations, aimed at diagnosing chromaffin
tumors.
RESULTS AND DISCUSSION
Pheochromocytomas and PGLs can be sporadic or associated to
hereditary syndromes. In our institution, all patients with appar-
ently sporadic PHEO and PGL are offered to perform genetic
screening to exclude a hereditary disease.
Extra-adrenal PGLs are the most frequent lesions found in
SDHB mutation carriers. Therefore, in these patients, genetic
analysis should start with SDHx genes sequencing. The sequenc-
ing might be preceded by a less expensive immunohistochemistry
on tumor tissue using an anti-SDHB antibody. In fact, a positive
immunostaining excludes the involvement of SDHx genes while
a negative one indicates the degradation of the complex due to a
mutation in the SDHB, SDHC, or SDHD genes (van Nederveen
et al., 2009).
In this report we described four novel mutations in the SDHB
gene in patients affected by extra-adrenal sPGLs (Table 1). Patient
1 was heterozygous for the p.Q30X,which consists in a C to T sub-
stitution in a glutamine coding triplet CAG that is then converted
in a stop codon. Patient 2 was heterozygous for the p.Y61X, which
consists in a T to A substitution in a tyrosine coding triplet TAT
that is then converted in a stop codon. Patient 3 was heterozygous
for the p.W201X, which consists in a G to A substitution in a tryp-
tophan coding triplet TGG that is then converted in a stop codon.
These mutations are predicted to encode for a truncated SDHB
protein. The fourth mutation is a S195del frameshift mutation,
which consists in a deletion of the codon AGC encoding for a
serine. These mutations were not detected in 124 normal alleles.
To our knowledge the mutations above described has not been
previously reported.
All four patients presented one or more symptoms related to
PHEO/PGL syndrome and in all arterial hypertension was found.
The biochemical examination revealed in all patients elevated con-
centrations of urinary catecholamines and plasma chromogranin-
A. Size and location of tumors were detailed by MRI, CT, and 123I-
MIBG. The diagnosis of extra-adrenal PGLs was then confirmed
at the pathological examination.
Extra-adrenal PHEOs, also known as sPGLs, account for
10–20% of catecholamine-producing tumors.
So far clinical and research studies have shown that SDHB
mutation carriers develop extra-adrenal PGLs in the most of cases
and metastatic disease in 30–50% of cases (Gimenez-Roqueplo
et al., 2003; Neumann et al., 2004; Timmers et al., 2007).
The highlights of this study are that all these patients with
apparently sporadic sPGL undergone SDH gene analysis were
SDHB mutation carriers and two of them developed malignant
traits with bone metastases. These findings strongly suggest to per-
form SDH gene analysis in all patients with apparently sporadic
sPGL and to perform a careful and periodical clinical follow-up in
those who result to be SDHB mutation carriers because of tumor
aggressive behavior.
The mechanisms by which SDHB mutations are more strongly
associated with extra-adrenal location, hormone activity, malig-
nancy and onset at an early age remain to be clarified.
Among the three SDHB mutated family members diagnosed
by the genetic screening, none presented clinical manifestations
of PGL, confirming the low penetrance of PGL-4 syndrome, as
reported in the literature.
In conclusion, these findings underline the central role of
genetic screening in patients affected by PHEOs or PGLs and
enlarge the list of SDHB mutations responsible for the presence of
these tumors. Apparently sporadic extra-adrenal sPGL have to be
preferentially tested for SDHB gene and SDHB mutated patients
have to be investigated for malignant disease.
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